Recent studies evaluated the effect of several innovative approaches such as FLT3 inhibitors, epigenetic agents and immunotherapy in MLL-R infant ALL, the results were still far from satisfactory (Brown, Pieters & Biondi, 2019). The gene discussed is FLT3; the disease is acute lymphoblastic leukemia.